Literature DB >> 1889458

The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules.

V Cerundolo1, T Elliott, J Elvin, J Bastin, H G Rammensee, A Townsend.   

Abstract

Peptides of various lengths derived from the influenza nucleoprotein (NP) bind to H-2Db class I molecules with affinities at 4 degrees C between approximately 3 x 10(5)- approximately 3 x 10(7) M-1. The peptide with the highest affinity corresponds to the sequence of nine amino acids (NP366-374) recently isolated from cells infected with influenza. This peptide forms stable complexes with half-lives greater than 110 h at 4 degrees C, 39 h at 22 degrees C and 3 h at 37 degrees C. Small increases in length of the peptide greatly reduce the stability of the complex (t1/2 approximately 1-10 h at 4 degrees C). These results may explain the homogeneous length of peptides isolated from class I molecules formed in vivo, and suggest that class I and II may differ in their dependence on the length of peptides for the formation of stable complexes.

Mesh:

Substances:

Year:  1991        PMID: 1889458     DOI: 10.1002/eji.1830210915

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease.

Authors:  J E Gairin; M B Oldstone
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 3.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263.

Authors:  Donald F Hunt; Robert A Henderson; Jeffrey Shabanowitz; Kazuyasu Sakaguchi; Hanspeter Michel; Noelle Sevilir; Andrea L Cox; Ettore Appella; Victor H Engelhard
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

5.  Variant antigenic peptide promotes cytotoxic T lymphocyte adhesion to target cells without cytotoxicity.

Authors:  D M Shotton; A Attaran
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Virus and cytotoxic T lymphocytes: crucial role of viral peptide secondary structure in major histocompatibility complex class I interactions.

Authors:  J E Gairin; M B Oldstone
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.

Authors:  R R Pogue; J Eron; J A Frelinger; M Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Solution binding of an antigenic peptide to a major histocompatibility complex class I molecule and the role of beta 2-microglobulin.

Authors:  L F Boyd; S Kozlowski; D H Margulies
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

10.  A subset of HLA-B27 molecules contains peptides much longer than nonamers.

Authors:  R G Urban; R M Chicz; W S Lane; J L Strominger; A Rehm; M J Kenter; F G UytdeHaag; H Ploegh; B Uchanska-Ziegler; A Ziegler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.